The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
Open accessAbstract
BACKGROUND: The Middle East respiratory syndrome coronavirus (MERS-CoV) has been reported to have a high case-fatality rate. Currently, there is no specific therapy or vaccine with proven effectiveness for MERS-CoV infections. METHODS: A combination of ribavirin and interferon therapy was used for the treatment of five MERS-CoV-positive patients. We reviewed the therapeutic schedule and the outcome of these patients. RESULTS: All patients were critically ill with acute respiratory distress syndrome treated with adjunctive corticosteroids and were on mechanical ventilation at the time of initiation of therapy. The median time from admission to therapy with ribavirin and interferon was 19 (range 10-22) days. None of the patients responded to the supportive or therapeutic interventions and all died of their illness. CONCLUSIONS: While ribavirin and interferon may be effective in some patients, our practical experience suggests that critically ill patients with multiple comorbidities who are diagnosed late in the course of their illness may not benefit from combination antiviral therapy as preclinical data suggest. There is clearly an urgent need for a novel effective antiviral therapy for this emerging global threat.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Self-citationHospital outbreak of Middle East respiratory syndrome coronavirus
Assiri, A., McGeer, A., Perl, T. M., Price, C. S., Al Rabeeah, A. A., Cummings, D. A. T., Alabdullatif, Z. N., Assad, M., Almulhim, A., Makhdoom, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306742 · Cited by 1,196
Self-citationIdentification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,017
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
Corman, V. M., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bludau, M., van Boheemen, S., Gopal, R., Ballhause, M., Bestebroer, T. M., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.39.20285-en · Cited by 561
Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections
Memish, Z. A., Zumla, A. I., Al-Hakeem, R. F., Al-Rabeeah, A. A., & Stephens, G. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303729 · Cited by 493
Self-citationTreatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
Falzarano, D., de Wit, E., Rasmussen, A. L., Feldmann, F., Okumura, A., Scott, D. P., Brining, D., Bushmaker, T., Martellaro, C., Baseler, L., et al. (2013) · Nature Medicine · doi:10.1038/nm.3362 · Cited by 445
Zhao, Z. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05320-0 · Cited by 407
Cited by
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Middle East respiratory syndrome
Zumla, A., Hui, D. S., & Perlman, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,263
MERS, SARS and other coronaviruses as causes of pneumonia
Yin, Y., & Wunderink, R. G. (2018) · Respirology · doi:10.1111/resp.13196 · Cited by 1,095
Zimmermann, P., & Curtis, N. (2020) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002660 · Cited by 1,077
Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2003.03011 · Cited by 1,001
Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19
Park, A., & Iwasaki, A. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.05.008 · Cited by 909
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
China National Clinical Research Center for Respiratory Diseases, Shen, K., National Center for Children’s Health, B., Group of Respirology, C. P. S., Chinese Medical Doctor Association Committee on Respirology Pediatrics, China Medicine Education Association Committee on Pediatrics, Chinese Research Hospital Association Committee on Pediatrics, Chinese Non-government Medical Institutions Association Committee on Pediatrics, China Association of Traditional Chinese Medicine, C. O. C. H. A. M. R., China News of Drug Information Association, C. O. C. S. M., et al. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-020-00343-7 · Cited by 791
Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
de Wilde, A. H., Jochmans, D., Posthuma, C. C., Zevenhoven-Dobbe, J. C., van Nieuwkoop, S., Bestebroer, T. M., van den Hoogen, B. G., Neyts, J., & Snijder, E. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03011-14 · Cited by 736
Badawi, A., & Ryoo, S. G. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.06.015 · Cited by 703
Helmy, Y. A., Fawzy, M., Elaswad, A., Sobieh, A., Kenney, S. P., & Shehata, A. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041225 · Cited by 692
Dyall, J., Coleman, C. M., Hart, B. J., Venkataraman, T., Holbrook, M. R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Jahrling, P. B., Laidlaw, M., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03036-14 · Cited by 660
Jamilloux, Y., Henry, T., Belot, A., Viel, S., Fauter, M., El Jammal, T., Walzer, T., François, B., & Sève, P. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102567 · Cited by 658
Chan, J. F.-W., Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., Li, F., Xiao, C., Gao, H., Yu, P., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv392 · Cited by 608
IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes
Channappanavar, R., Fehr, A. R., Zheng, J., Wohlford-Lenane, C., Abrahante, J. E., Mack, M., Sompallae, R., McCray, P. B., Meyerholz, D. K., & Perlman, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126363 · Cited by 556
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493
Self-citationTotura, A. L., Whitmore, A., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 455
Interplay between SARS-CoV-2 and the type I interferon response
Sa Ribero, M., Jouvenet, N., Dreux, M., & Nisole, S. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1008737 · Cited by 443
MERS coronavirus: diagnostics, epidemiology and transmission
Mackay, I. M., & Arden, K. E. (2015) · Virology Journal · doi:10.1186/s12985-015-0439-5 · Cited by 388
Recent discovery and development of inhibitors targeting coronaviruses
Pillaiyar, T., Meenakshisundaram, S., & Manickam, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.015 · Cited by 361
Hu, Y., Li, W., Gao, T., Cui, Y., Jin, Y., Li, P., Ma, Q., Liu, X., & Cao, C. (2017) · Journal of Virology · doi:10.1128/jvi.02143-16 · Cited by 294
Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus
Fehr, A. R., Channappanavar, R., & Perlman, S. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-031152 · Cited by 293
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
And the MIRACLE trial group, Arabi, Y. M., Alothman, A., Balkhy, H. H., Al-Dawood, A., AlJohani, S., Al Harbi, S., Kojan, S., Al Jeraisy, M., Deeb, A. M., et al. (2018) · Trials · doi:10.1186/s13063-017-2427-0 · Cited by 253
Nucleoside analogues for the treatment of coronavirus infections
Pruijssers, A. J., & Denison, M. R. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.002 · Cited by 196
Metadata
- Authors
- Al-Tawfiq, J. A., Momattin, H., Dib, J., & Memish, Z. A.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 20
- Pages
- 42-46
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W2035958898
- Cited by
- 322
- References
- 24
- FWCI
- 24.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.